Skip Navigation

A Phase IB/II, Open Label, Umbrella Study Of Elranatamab PF06863135, A B-Cell Maturation Antigen BCMA CD3 Bispecific Antibody, In Combination With Other Anticancer Treatments In Participants With Multiple Myeloma

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT05090566

Study #:
STUDY00148762

Start Date:
Nov 14, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05090566

View Complete Trial Details & Eligibility at ClinicalTrials.gov